TECTONIC THERAPEUTIC, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
TECTONIC THERAPEUTIC, INC. (TECX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 2.75 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- TECTONIC THERAPEUTIC, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 2.66M shares, a 32.44% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 2.01M shares, a 67.24% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-09-30 was 1.81M shares, a 60.06% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-06-30 was 1.96M shares, a 56.90% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 2.21M shares.
- TECTONIC THERAPEUTIC, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 6.19M shares, a 40.29% decline from fiscal 2022.
- TECTONIC THERAPEUTIC, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 10.36M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 2.75M shares 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | 2.66M shares 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | 2.21M shares 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | 2.20M shares 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | 2.03M shares 10-Q · filed 2026-08-06 | ||||
| 2025-03-31 | 2.01M shares 10-Q · filed 2025-05-08 | ||||
| 2024-12-31 | 2.01M shares 10-Q · filed 2026-05-07 | 1.65M shares 10-K · filed 2025-03-20 | |||
| 2024-09-30 | 1.81M shares 10-Q · filed 2024-11-12 | 1.81M shares 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | 1.96M shares 10-Q · filed 2024-08-14 | 1.96M shares 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | 6.12M shares 10-Q · filed 2025-05-08 | ||||
| 2023-12-31 | 6.19M shares 10-K · filed 2025-03-20 | 4.43M shares 10-K · filed 2024-03-14 | |||
| 2023-09-30 | 4.52M shares 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | 4.54M shares 10-Q · filed 2024-08-14 | 4.54M shares 10-Q · filed 2024-08-14 | |||
| 2022-12-31 | 10.36M shares 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |